Valsartan in Ischemic Dilated Cardiomyopathy

Guideline Recommendations

The American College of Cardiology/American Heart Association guidelines specifically recommend valsartan and candesartan as the ARBs with established efficacy for heart failure after myocardial infarction 1
ARBs should be prescribed at discharge for STEMI patients who are intolerant of ACE inhibitors and have either clinical or radiological signs of heart failure and LVEF <0.40 (Class I recommendation, Level of Evidence B) 1
In patients who tolerate ACE inhibitors, valsartan can be used as an alternative in the long-term management of STEMI patients with heart failure or LVEF <0.40 (Class IIa recommendation) 1
For patients with ischemic DCM and preserved EF, the usefulness of ARBs like valsartan in treating symptoms (angina and dyspnea) is not well established (Class 2b recommendation) 2

In the VALIANT trial, valsartan was shown to be as effective as captopril in patients at high risk for cardiovascular events after myocardial infarction, establishing its efficacy specifically for post-MI left ventricular dysfunction 3, 4
ACE inhibitors remain the first-line therapy for inhibition of the renin-angiotensin-aldosterone system in patients with ischemic DCM, with ARBs (specifically valsartan) recommended when patients are intolerant to ACE inhibitors 3
In the VALUE trial, valsartan-based therapy was comparable to amlodipine-based therapy in terms of cardiac mortality and morbidity in patients with hypertension and high risk of cardiovascular events 5
Sacubitril/valsartan has shown superior outcomes compared to ACE inhibitors alone in patients with LVEF ≤35% (of which 60% had ischemic etiology), reducing heart failure hospitalization and cardiovascular death 6

Sacubitril/valsartan may decrease myocardial ischemia through its effect in reducing LV wall stress and improving coronary circulation, with post-hoc analyses showing reduced risk of coronary events compared to ACE inhibitors 6

The combination of an ACE inhibitor and valsartan is not generally recommended as it increases adverse effects without providing additional benefits 4
For younger patients (≤45 years) with nonobstructive HCM due to a pathogenic cardiac sarcomere genetic variant and mild phenotype, valsartan may be beneficial to slow adverse cardiac remodeling 2
Valsartan should be part of a comprehensive treatment approach for ischemic DCM that includes beta-blockers, aldosterone antagonists, and in appropriate patients, SGLT2 inhibitors 7

The American College of Cardiology recommends valsartan as the preferred angiotensin receptor blocker (ARB) for patients with ischemic dilated cardiomyopathy due to its established efficacy in post-myocardial infarction left ventricular dysfunction and heart failure 8
Valsartan has demonstrated efficacy specifically in post-myocardial infarction patients with left ventricular dysfunction in the VALIANT trial, making it particularly suitable for ischemic DCM 8

The American College of Cardiology and American Heart Association guidelines state that only valsartan and candesartan have established efficacy for heart failure after myocardial infarction 9
Candesartan is an alternative option with demonstrated efficacy in heart failure, particularly in patients intolerant to ACE inhibitors (CHARM Alternative trial) 10
Losartan at 50 mg daily was found to be less effective than captopril in the OPTIMAAL trial, suggesting it may not be the optimal choice for ischemic DCM 11

The American Heart Association recommends that ACE inhibitors remain first-line therapy for inhibition of the renin-angiotensin system in patients with ischemic DCM, with ARBs (specifically valsartan) used when patients are intolerant to ACE inhibitors 10, 12
An ARB should be administered early in patients with STEMI and hypertension, particularly with anterior MI, persistent hypertension, LV dysfunction, heart failure, or diabetes mellitus 13, 12

The American College of Cardiology recommends that beta-blockers should be administered to all stable patients with ischemic DCM and reduced ejection fraction 14
Aldosterone antagonists (spironolactone or eplerenone) should be added in patients with LVEF ≤40% and either symptomatic heart failure or diabetes, provided renal function is adequate 12, 11
High-intensity statin therapy should be initiated in all patients with ischemic DCM 12
In patients with diabetes and ischemic DCM, SGLT2 inhibitors (empagliflozin, canagliflozin, or dapagliflozin) should be considered as they have shown cardiovascular benefits 15
For patients with persistent symptoms despite optimal therapy with ACE inhibitors/ARBs, beta-blockers, and MRAs, sacubitril/valsartan (ARNI) should be considered as replacement therapy 14